Log in

Bristol-Myers Squibb Stock Forecast, Price & News

-0.38 (-0.60 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $62.84
50-Day Range
MA: $69.10
52-Week Range
Now: $62.84
Volume9.52 million shs
Average Volume13.54 million shs
Market Capitalization$142.19 billion
P/E RatioN/A
Dividend Yield2.85%
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, and Ubiquigent Limited; clinical collaboration agreement with NeoImmuneTech, Inc.; and partnership with Astrazeneca Plc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
Bristol-Myers Squibb logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 2.5Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.24 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$26.15 billion
Cash Flow$4.48 per share
Book Value$22.20 per share


Net Income$3.44 billion


Outstanding Shares2,262,690,000
Market Cap$142.19 billion
Next Earnings Date2/4/2021 (Estimated)
-0.38 (-0.60 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock been impacted by Coronavirus (COVID-19)?

Bristol-Myers Squibb's stock was trading at $108.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BMY shares have decreased by 41.9% and is now trading at $62.84.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Bristol-Myers Squibb?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bristol-Myers Squibb

What stocks does MarketBeat like better than Bristol-Myers Squibb?

Wall Street analysts have given Bristol-Myers Squibb a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bristol-Myers Squibb wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Bristol-Myers Squibb

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) issued its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the Zacks' consensus estimate of $1.49 by $0.14. The biopharmaceutical company earned $10.54 billion during the quarter, compared to analysts' expectations of $10.33 billion. Bristol-Myers Squibb had a positive return on equity of 27.48% and a negative net margin of 0.11%. The business's quarterly revenue was up 75.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.17 earnings per share.
View Bristol-Myers Squibb's earnings history

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, September 10th. Investors of record on Friday, October 2nd will be given a dividend of $0.45 per share on Monday, November 2nd. This represents a $1.80 annualized dividend and a dividend yield of 2.86%. The ex-dividend date is Thursday, October 1st.
View Bristol-Myers Squibb's dividend history

When did Bristol-Myers Squibb's stock split? How did Bristol-Myers Squibb's stock split work?

Bristol-Myers Squibb's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY21 earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of $7.15-7.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.41.

What price target have analysts set for BMY?

16 Wall Street analysts have issued 1-year price targets for Bristol-Myers Squibb's shares. Their forecasts range from $65.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $74.20 in the next twelve months. This suggests a possible upside of 18.1% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 15,710,000 shares, an increase of 14.3% from the October 15th total of 13,750,000 shares. Based on an average daily trading volume, of 10,400,000 shares, the short-interest ratio is presently 1.5 days.
View Bristol-Myers Squibb's Short Interest

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 55, Pay $6.22M)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 52, Pay $3.62M)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 59, Pay $2.92M)
  • Dr. Christopher S. Boerner, Exec. VP & Chief Commercialization Officer (Age 49, Pay $2.49M)
  • Mr. Rupert Vessey M.A., Exec. VP and Pres of Research & Early Devel. (Age 55, Pay $3.31M)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a number of retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.46%), Swiss National Bank (0.39%), New York State Common Retirement Fund (0.21%), Standard Life Aberdeen plc (0.21%), California State Teachers Retirement System (0.19%) and Principal Financial Group Inc. (0.16%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Dinesh C Paliwal, Ernest Mario, Giovanni Caforio, James J Loughlin, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Rupert Vessey, Sandra Leung, Terrie Curran and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including AJO LP, State of Tennessee Treasury Department, Jennison Associates LLC, Charles Schwab Investment Management Inc., Los Angeles Capital Management & Equity Research Inc., Hexavest Inc., Public Sector Pension Investment Board, and Voloridge Investment Management LLC. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, Giovanni Caforio, John E Elicker, Joseph Eid, Louis S Schmukler, Rupert Vessey, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was acquired by a variety of institutional investors in the last quarter, including AustralianSuper Pty Ltd, Federated Hermes Inc., Polar Capital LLP, Polar Capital LLP, Rothschild & Co. Asset Management US Inc., Cornerstone Investment Partners LLC, Cambiar Investors LLC, and Caisse DE Depot ET Placement DU Quebec. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Ernest Mario, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $62.84.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $142.19 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.